SCHEMBL1264466

SCHEMBL1264466

CC(C)(C)c1ccc(S(=O)(=O)N2CCc3cc(C(=O)NO)cc(F)c3C2)cc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 8/20 0.60
HDAC8 Q9BY41 4/20 0.42
HDAC3 O15379 3/20 0.42
HDAC11 Q96DB2 2/20 0.42
TRPV4 Q9HBA0 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD11B1 P28845 2/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
GPR183 P32249 1/20 0.42
HDAC1 Q13547 1/20 0.41
OPRK1 P41145 1/20 0.41
STAT3 P40763 1/20 0.40
IGF1R P08069 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1263313 0.89 HDAC6 (0.58) HDAC6HDAC8HDAC3HDAC11TRPV4
SCHEMBL1262981 0.88 HDAC6 (0.57) HDAC6HDAC8HDAC3HDAC11TRPV4
SCHEMBL12895917 0.86 HDAC6 (0.56) HDAC6TRPV4KDM4EALDH1A1MAPT
SCHEMBL1264273 0.83 HDAC6 (0.50) HDAC6KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL1263768 0.83 HDAC6 (0.80) HDAC6HDAC8HDAC3HDAC11KDM4E
SCHEMBL7866689 0.83 HDAC6 (0.49) HDAC6MAPTSMN1; SMN2LMNAGAA
SCHEMBL1264143 0.80 HDAC6 (0.71) HDAC6HDAC8HDAC3HDAC11TRPV4
SCHEMBL10224348 0.80 HDAC6 (0.57) HDAC6HDAC8HDAC3HDAC11TRPV4
SCHEMBL1264026 0.78 HDAC6 (0.71) HDAC6HDAC8HDAC3HDAC11TRPV4
SCHEMBL1173781 0.77 HDAC6 (0.56) HDAC6HDAC8HDAC3HDAC11TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445340-B1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARM INC (US) 2016-05-18 EP claimed
EP-2445340-B1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARM INC (US) 2016-05-18 EP disclosed
US-9321731-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-04-26 US disclosed
US-9321731-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-04-26 US disclosed
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-04 US disclosed
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-04 US disclosed
US-9096518-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-9096518-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed
US-20110039827-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039827-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 HDAC6 1/4885HDAC8 11/4885HDAC3 4/4885
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 HDAC6 1/4885HDAC8 11/4885HDAC3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.